Ph.D. Dinesh V Patel - 02 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
President and CEO, Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Issuer symbol
PTGX
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 19:38:09 UTC
Previous filing
24 Nov 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PATEL DINESH V PH D President and CEO, Director C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D. 06 Jan 2026 0001120477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +95,400 +18% $0.000000 614,943 02 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 +120,200 $0.000000 120,200 02 Jan 2026 Common Stock 120,200 $87.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F2 The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.